RWRuth Anne Laura Willems

Ruth Anne Laura Willems

*This is an algorithmically generated author record based on publicly available information.

Ruth Anne Laura Willems has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Bas de Laat

    Department of Functional Coagulation, Synapse Research Institute, Maastricht, The Netherlands

    2 shared publications
  • Hugo Ten Cate

    Thrombosis Expert Center Maastricht, Maastricht University Medical Center, Maastricht, The Netherlands

    2 shared publications
  • Judith de Vos-Geelen

    Div. Medical Oncology, Dept. Internal Medicine, GROW - Research Institute for Oncology & Reproduction, Maastricht University Medical Centre, Maastricht, the Netherlands

    2 shared publications
  • Mark Roest

    Synapse Research Institute, Maastricht, The Netherlands

    2 shared publications
  • Bas Groot Koerkamp

    Department of Surgery, Erasmus Medical Center, Rotterdam, the Netherlands

    1 shared publication
  • Bas de Laat

    Department of Functional Coagulation, Synapse Research Institute, Maastricht, The Netherlands; Cardiovascular Research Institute Maastricht (CARIM), School for Cardiovascular Diseases, Maastricht, The Netherlands; Department of Platelet Pathophysiology, Synapse Research Institute, Maastricht, The Netherlands

    1 shared publication

Latest Publications

  • Altered whole blood thrombin generation and hyperresponsive platelets in patients with pancreatic cancer

    by Ruth Anne Laura Willems, Joke Konings, Dana Huskens, Harmen Middelveld, Nicol Pepels-Aarts, Lisa Verbeet, Phillip Gerrit de Groot, Johan Willem Marie Heemskerk, Hugo Ten Cate, Judith de Vos-Geelen, et al.


  • Cellular Components Contributing to the Development of Venous Thrombosis in Patients with Pancreatic Cancer

    by Ruth Anne Laura Willems, Charlotte Biesmans, Elena Campello, Paolo Simioni, Bas de Laat, Judith de Vos-Geelen, Mark Roest, Hugo Ten Cate

    Pancreatic ductal adenocarcinoma (PDAC) is an aggressive type of cancer and has a poor prognosis. Patients with PDAC are at high risk of developing thromboembolic events, which is a leading cause of morbidity and mortality following cancer progression. Plasma-derived coagulation is the most studied process in cancer-associated thrombosis. Other blood components, such as platelets, red blood cells, and white blood cells, have been gaining less attention. This narrative review addresses the literature on the role of cellular components in the development of venous thromboembolism (VTE) in patients with PDAC. Blood cells seem to play an important role in the development of VTE. Altered blood cell counts, i.e., leukocytosis, thrombocytosis, and anemia, have been found to associate with VTE risk. Tumor-related activation of leukocytes leads to the release of tissue factor-expressing microvesicles and the formation of neutrophil extracellular traps, initiating coagulation and forming a scaffold for thrombi. Tissue factor-expressing microvesicles are also thought to be released by PDAC cells. PDAC cells have been shown to stimulate platelet activation and aggregation, proposedly via the secretion of podoplanin and mucins. Hypofibrinolysis, partially explained by increased plasminogen activator inhibitor-1 activity, is observed in PDAC. In short, PDAC-associated hypercoagulability is a complex and multifactorial process. A better understanding of cellular contributions to hypercoagulability might lead to the improvement of diagnostic tests to identify PDAC patients at highest risk of VTE. * Equally contributed and joint first authors. Article published online: 04 December 2023 © 2023. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA


  • Open Access

    Venous Thromboembolism and Primary Thromboprophylaxis in Perioperative Pancreatic Cancer Care

    by R. A. L. Willems, N. Michiels, V. R. Lanting, S. Bouwense, B. L. J. van Den Broek, M. Graus, F. A. Klok, B. Groot Koerkamp, B. de Laat, M. Roest, et al.

    Recent studies have shown that patients with pancreatic ductal adenocarcinoma (PDAC) treated with neoadjuvant chemo(radio)therapy followed by surgery have an improved outcome compared to patients treated with upfront surgery. Hence, patients with PDAC are more and more frequently treated with chemotherapy in the neoadjuvant setting. PDAC patients are at a high risk of developing venous thromboembolism (VTE), which is associated with decreased survival rates. As patients with PDAC were historically offered immediate surgical resection, data on VTE incidence and associated preoperative risk factors are scarce. Current guidelines recommend primary prophylactic anticoagulation in selected groups of patients with advanced PDAC. However, recommendations for patients with (borderline) resectable PDAC treated with chemotherapy in the neoadjuvant setting are lacking. Nevertheless, the prevention of complications is crucial to maintain the best possible condition for surgery. This narrative review summarizes current literature on VTE incidence, associated risk factors, risk assessment tools, and primary thromboprophylaxis in PDAC patients treated with neoadjuvant chemo(radio)therapy.